NDI-031407 is under clinical development by Nimbus Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NDI-031407’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NDI-031407 overview

NDI-031407 is under development for the treatment of psoriasis and ankylosing spondylitis. It is based on proprietary computational drug discovery technology enabled rapid identification of potent and selective drug candidate for previously inaccessible target. The drug candidate targets tyrosine kinase 2. It was also under development for the treatment of unspecified cancer and inflammatory bowel disease including Crohn's disease.

Nimbus Therapeutics overview

Nimbus Therapeutics, formerly Nimbus Discovery, is a biotechnology company that develops small molecule medicines to treat immunology, oncology and metabolic disorders. The company is investigating TYK2 (tyrosine kinase 2) inhibitor targeting auto-immune disorders such as Crohn’s disease, psoriasis, multiple sclerosis and rheumatoid arthritis; HPK1 (hematopoietic progenitor kinase 1) inhibitor for the treatment of immuno-oncology diseases; ACLY (ATP citrate lyase), targeting cancer, metabolic and cardiovascular diseases; and AMPK (AMP-activated protein kinase) to treat metabolic disorders. Its pipeline programs include WRN (Werner syndrome helicase), a helicase used for treating microsatellite-instability (MSI) high tumors; Cbl-b (Casitas B-cell lymphoma), an E3 ubiquitin ligase, targeting immuno-oncology diseases; CTPS1 (CTP synthase 1) enzyme in lymphocytes to treat T and B cell-driven diseases. Nimbus Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of NDI-031407’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.